CytomX Therapeutics (CTMX) Gains from Investment Securities (2014 - 2026)

CytomX Therapeutics has reported Gains from Investment Securities for 13 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 329.38% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (up 329.38% YoY), and the FY2025 full-year result was $16.7 million, up 14.74% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $2.6 million, down from $16.7 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $16.7 million in Q4 2025, with the low at $463350.0 in Q3 2025.
• Historically, Gains from Investment Securities has averaged $7.4 million across 5 years, with a median of $5.0 million in 2022.
• Annual changes were most pronounced in 2025 — Gains from Investment Securities slumped 96.82% — and 2026, when it soared 329.38%.
• CytomX Therapeutics' Gains from Investment Securities stood at $13.3 million in 2022, then decreased by 2.56% to $12.9 million in 2023, then climbed by 12.45% to $14.6 million in 2024, then gained by 14.74% to $16.7 million in 2025, then plunged by 84.37% to $2.6 million in 2026.
• The last three Gains from Investment Securities figures came in at $2.6 million (Q1 2026), $16.7 million (Q4 2025), and $463350.0 (Q3 2025), per Business Quant data.